HomeCompareABT vs NOC

ABT vs NOC: Dividend Comparison 2026

ABT yields 2.36% · NOC yields 1.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $421.6K in total portfolio value
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
NOC
NOC
● Live price
1.38%
Share price
$671.59
Annual div
$9.24
5Y div CAGR
58%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.0K
Annual income
$45,261.73
Full NOC calculator →

Portfolio growth — ABT vs NOC

📍 ABT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTNOC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + NOC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
NOC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
NOC
Annual income on $10K today (after 15% tax)
$116.95/yr
After 10yr DRIP, annual income (after tax)
$38,472.47/yr
At 15% tax rate, ABT beats the other by $240,983.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + NOC for your $10,000?

ABT: 50%NOC: 50%
100% NOC50/50100% ABT
Portfolio after 10yr
$322.8K
Annual income
$187,016.89/yr
Blended yield
57.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABT right now

ABT
Analyst Ratings
30
Buy
10
Hold
Consensus: Buy
Price Target
$137.67
+35.1% upside vs current
Range: $120.00 — $158.00
Altman Z
4.9
Piotroski
6/9
NOC
Analyst Ratings
20
Buy
14
Hold
1
Sell
Consensus: Buy
Price Target
$736.31
+9.6% upside vs current
Range: $623.00 — $815.00
Altman Z
3.3
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
NOC buys
0
No recent congressional trades found for ABT or NOC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTNOC
Forward yield2.36%1.38%
Annual dividend / share$2.40$9.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%58%
Portfolio after 10y$533.6K$112.0K
Annual income after 10y$328,772.04$45,261.73
Total dividends collected$492.4K$85.7K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyBuy
Analyst price target$137.67$736.31

Year-by-year: ABT vs NOC ($10,000, DRIP)

YearABT PortfolioABT Income/yrNOC PortfolioNOC Income/yrGap
1← crossover$11,084$384.43$10,917$217.38+$167.00ABT
2$12,510$649.94$12,032$350.44+$478.00ABT
3$14,505$1,118.82$13,445$570.31+$1.1KABT
4$17,499$1,978.53$15,327$941.01+$2.2KABT
5$22,364$3,640.59$17,984$1,584.04+$4.4KABT
6$31,026$7,096.70$21,987$2,744.54+$9.0KABT
7$48,215$15,016.56$28,481$4,954.86+$19.7KABT
8$87,182$35,592.30$39,952$9,477.48+$47.2KABT
9$191,446$98,161.15$62,380$19,631.40+$129.1KABT
10$533,619$328,772.04$112,009$45,261.73+$421.6KABT

ABT vs NOC: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

NOCIndustrials

Northrop Grumman Corporation operates as an aerospace and defense company worldwide. The company's Aeronautics Systems segment designs, develops, manufactures, integrates, and sustains aircraft systems. This segment also offers unmanned autonomous aircraft systems, including high-altitude long-endurance strategic ISR systems and vertical take-off and landing tactical ISR systems; and strategic long-range strike aircraft, tactical fighter and air dominance aircraft, and airborne battle management and command and control systems. Its Defense Systems segment designs, develops, and produces weapons and mission systems. It offers products and services, such as integrated battle management systems, weapons systems and aircraft, and mission systems. This segment also provides command and control and weapons systems, including munitions and missiles; precision strike weapons; propulsion, such as air-breathing and hypersonic systems; gun systems and precision munitions; life cycle service and support for software, weapons systems, and aircraft; and logistics support, sustainment, operation, and modernization for air, sea, and ground systems. The company's Mission Systems segment offers cyber, command, control, communications and computers, intelligence, surveillance, and reconnaissance systems; radar, electro-optical/infrared and acoustic sensors; electronic warfare systems; advanced communications and network systems; cyber solutions; intelligence processing systems; navigation; and maritime power, propulsion, and payload launch systems. This segment also provides airborne multifunction sensors; maritime/land systems and sensors; navigation, targeting, and survivability solutions; and networked information solutions. Its Space Systems segment offers satellites and payloads; ground systems; missile defense systems and interceptors; launch vehicles and related propulsion systems; and strategic missiles. The company was founded in 1939 and is based in Falls Church, Virginia.

Full NOC Calculator →
📬

Get this ABT vs NOC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.